“…5 Menaquinone biosynthesis is therefore an attractive target for antibiotic development, 6 and inhibitors against Gram-positive organisms such as Mycobacterium tuberculosis and Staphylococcus aureus have been identified. 7 The recent discovery of a new, futalosine-dependent, menaquinone biosynthesis pathway has presented new opportunities for antibacterial development 8,9 because important human pathogens including Helicobacter pylori (causes gastric ulcers and cancer), Campylobacter jejuni (causes diarrhea), Chlamydia strains (cause urethritis and respiratory tract infections), and Spirochetes (cause syphilis and Lyme disease) utilize this pathway. 10 The absence of this pathway in humans and in most of the human gut bacteria potentially provides the required selectivity for targeting this pathway without affecting the commensal bacteria.…”